Clinical Trials

The VITAL trial explained: what vitamin D and omega-3 did — and didn't do

Nearly 26,000 participants, over five years, testing two of the most widely used supplements in the world against cardiovascular events, cancer, and death. Here is what the trial actually found on each endpoint.

July 26, 2026  ·  9 min read

The CALERIE trial: what human caloric restriction data actually shows

Caloric restriction is the oldest and most robustly validated longevity intervention in non-human animals. CALERIE is the closest thing to a definitive human RCT — and what it found is more nuanced than "eat less, live longer."

July 26, 2026  ·  8 min read

The ABLE trial: what to expect from alpha-ketoglutarate's first real RCT

Alpha-ketoglutarate's evidence tier has been stuck at Emerging on a single uncontrolled trial. A placebo-controlled RCT is what would actually move it — here's what that trial is designed to answer.

July 26, 2026  ·  7 min read

Jardiance (empagliflozin) and longevity: reading the brand-name evidence

Jardiance is the brand name most patients search for, but the underlying trial evidence belongs to empagliflozin and the broader SGLT2 inhibitor class. Here is how to read brand-name searches against generic-class evidence.

July 26, 2026  ·  7 min read

Ozempic and Wegovy for longevity: what the brand-name semaglutide evidence shows

Ozempic and Wegovy are both semaglutide, at different doses and indications. Here is how their shared trial evidence, including SELECT, maps onto longevity-relevant claims.

July 26, 2026  ·  8 min read

GlyNAC dosing in published trials: what researchers have actually studied

A summary of the glycine and N-acetylcysteine dosing regimens used in published GlyNAC longevity trials. This describes what researchers have studied — it is not a dosing recommendation.

July 25, 2026  ·  7 min read

The ACCORD trial: what it taught longevity medicine about intensive glucose control

The ACCORD trial found that intensive glucose lowering increased all-cause mortality in high-risk type 2 diabetes patients. It is one of the most important cautionary data points in metabolic longevity medicine.

July 19, 2026  ·  11 min read

The PEARL trial explained: rapamycin, immune function, and what the 2024 results mean

The PEARL trial is the most important published human trial of rapamycin for aging to date. Here is a detailed breakdown of the design, results, and what they do and do not establish.

July 19, 2026  ·  12 min read

TAME trial 2026 update: where the metformin longevity trial stands

The Targeting Aging with Metformin trial is the most significant longevity trial running. Here is the current enrollment status, timeline, and what interim signals look like.

July 19, 2026  ·  11 min read

The LIFE study: what the largest exercise trial in older adults found

The Lifestyle Interventions and Independence for Elders study is the most rigorous RCT of physical activity in older adults at risk of mobility disability. What it found — and what it means for longevity medicine.

July 19, 2026  ·  10 min read

EMPA-REG OUTCOME explained: what the empagliflozin trial showed for cardiovascular and longevity medicine

The EMPA-REG OUTCOME trial produced one of the most surprising cardiovascular results in recent clinical trial history. Here is a full breakdown of what it found and why it matters for longevity medicine.

July 19, 2026  ·  11 min read

DECLARE-TIMI 58: dapagliflozin, cardiovascular outcomes, and the longevity implications

DECLARE-TIMI 58 tested dapagliflozin in a broader, lower-risk population than EMPA-REG. Here is what it found, how it compares, and what the implications are for longevity use.

July 19, 2026  ·  11 min read

SELECT trial full breakdown: semaglutide, cardiovascular death, and the longevity question

The SELECT trial showed semaglutide reduced major adverse cardiovascular events in non-diabetic obese adults. Here is the full breakdown of what the trial showed and what it means for longevity medicine.

July 19, 2026  ·  12 min read

Could semaglutide become an anti-aging drug? The SELECT trial and beyond

Semaglutide's weight-loss story is well known. The cardiovascular outcome data is the more significant — and less discussed — longevity story.

June 24, 2026  ·  11 min read

Rapamycin dosing in published clinical trials: what the research has actually tested

A summary of dosing regimens used in published rapamycin longevity trials. This describes what researchers have studied — it is not a dosing recommendation.

June 24, 2026  ·  10 min read